Tesaro's Zejula Expansion Includes Keytruda Combo, Lung Cancer

The company, encouraged by positive Phase I data from a trial testing the PARP inhibitor niraparib in combination with Merck's PD-1 inhibitor Keytruda in recurrent ovarian cancer, plans to initiate a larger trial by the end of the year or early in 2018.

Tesaro Inc. is moving forward with ambitions to expand the poly ADP-ribose polymerase (PARP) inhibitor Zejula (niraparib) to more indications beyond recurrent ovarian cancer, including as a front-line treatment for ovarian cancer, in combination with the immunotherapy Keytruda (pembrolizumab), in triple-negative breast cancer and lung cancer.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

18 Apr 2025

• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Leqembi Launch Set For Germany And Austria As EU Approval Finally Comes

16 Apr 2025

• By Neena Brizmohun

Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.

Pipeline Watch: Ten Approvals And Eleven Phase III Readouts

14 Apr 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.